Published in Cancer Res on August 01, 2003
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab (2008) 5.94
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA (2013) 5.71
Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer (2013) 4.46
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest (2008) 3.98
Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov (2012) 3.09
Health disparities in endocrine disorders: biological, clinical, and nonclinical factors--an Endocrine Society scientific statement. J Clin Endocrinol Metab (2012) 2.78
Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest (2005) 2.77
The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg (2007) 2.36
Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid (2010) 2.05
Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts. Cancer Res (2005) 1.93
Do benign thyroid nodules have malignant potential? An evidence-based review. World J Surg (2008) 1.85
A susceptibility locus for papillary thyroid carcinoma on chromosome 8q24. Cancer Res (2009) 1.77
Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch (2005) 1.62
BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab (2012) 1.39
Thyroid cancer gender disparity. Future Oncol (2010) 1.36
Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab (2008) 1.31
High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res (2009) 1.29
BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg (2012) 1.23
Detection of mutant BRAF alleles in the plasma of patients with metastatic melanoma. J Mol Diagn (2007) 1.18
Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas. Curr Genomics (2011) 1.18
Expression of hypoxia-inducible factor 1 alpha in thyroid carcinomas. Endocr Relat Cancer (2010) 1.15
Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants. Haematologica (2013) 1.11
Efficacy of IGFBP7 for treatment of metastatic melanoma and other cancers in mouse models and human cell lines. Mol Cancer Ther (2009) 1.10
Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann Surg (2006) 1.09
Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer. Thyroid (2009) 1.07
Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules. Cytojournal (2006) 1.06
Oncogenic activation of MAP kinase by BRAF pseudogene in thyroid tumors. Neoplasia (2009) 1.06
3'-deoxy-3'-[18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition. Cancer Res (2007) 1.04
Loss of Rap1GAP in papillary thyroid cancer. J Clin Endocrinol Metab (2008) 1.02
Thyroid cancer cell lines: an overview. Front Endocrinol (Lausanne) (2012) 1.02
Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance. Adv Enzyme Regul (2007) 1.01
Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loop-hybrid mobility shift assay. J Mol Diagn (2006) 0.99
Sensitive detection of BRAF V600E mutation by Amplification Refractory Mutation System (ARMS)-PCR. Biomark Res (2013) 0.98
3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer. J Nucl Med (2013) 0.97
BRAFV600E mutation and papillary thyroid cancer: chicken or egg? J Clin Endocrinol Metab (2012) 0.95
BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Arch (2004) 0.95
Cross-regulation between oncogenic BRAF(V600E) kinase and the MST1 pathway in papillary thyroid carcinoma. PLoS One (2011) 0.93
Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion. Endocr Relat Cancer (2010) 0.93
Clinicopathological and molecular histochemical review of skull base metastasis from differentiated thyroid carcinoma. Acta Histochem Cytochem (2013) 0.92
Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma. Clin Cancer Res (2013) 0.92
Genome haploidisation with chromosome 7 retention in oncocytic follicular thyroid carcinoma. PLoS One (2012) 0.92
Early onset MSI-H colon cancer with MLH1 promoter methylation, is there a genetic predisposition? BMC Cancer (2010) 0.91
BRAF mutation-specific promoter methylation of FOX genes in colorectal cancer. Clin Epigenetics (2013) 0.89
Genetics of papillary thyroid cancer initiation: implications for therapy. Trans Am Clin Climatol Assoc (2005) 0.88
Nuclear factor κB-dependent regulation of angiogenesis, and metastasis in an in vivo model of thyroid cancer is associated with secreted interleukin-8. J Clin Endocrinol Metab (2014) 0.88
Inflammation in thyroid oncogenesis. Am J Cancer Res (2012) 0.87
Neurofibroma adjacent to the thyroid gland and a thyroid papillary carcinoma in a patient with neurofibromatosis type 1: report of a case. Surg Today (2009) 0.86
Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients. Oncologist (2015) 0.86
Association of BRAFV600E mutation with clinicopathological features of papillary thyroid carcinoma: a study on a Chinese population. Int J Clin Exp Pathol (2014) 0.86
The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors. World J Surg Oncol (2013) 0.85
Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot. World J Surg (2008) 0.84
Differential diagnosis of thyroid nodules using fine-needle aspiration cytology and oncogene mutation screening: are we ready? F1000 Med Rep (2010) 0.83
The role of epigenetic alterations in papillary thyroid carcinogenesis. J Thyroid Res (2011) 0.83
Detection of BRAF V600E activating mutation in papillary thyroid carcinoma using PCR with allele-specific fluorescent probe melting curve analysis. J Clin Pathol (2007) 0.83
Induction of heparanase-1 expression by mutant B-Raf kinase: role of GA binding protein in heparanase-1 promoter activation. Neoplasia (2010) 0.82
Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma. World J Surg Oncol (2013) 0.82
The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases. Virchows Arch (2011) 0.81
A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth. J Clin Endocrinol Metab (2015) 0.80
Recent progress of genome study for anaplastic thyroid cancer. Genomics Inform (2013) 0.80
[Molecular pathology of thyroid tumors]. Pathologe (2010) 0.80
Suitability of animal models for studying radiation-induced thyroid cancer in humans: evidence from nuclear architecture. Thyroid (2011) 0.79
BRAFV600E status and clinical characteristics in solitary and multiple papillary thyroid carcinoma: experience of 512 cases at a clinical center in China. World J Surg Oncol (2012) 0.79
Polymorphisms of the BRAF gene predispose males to malignant melanoma. J Carcinog (2003) 0.79
Prediction Table and Nomogram as Tools for Diagnosis of Papillary Thyroid Carcinoma: Combined Analysis of Ultrasonography, Fine-Needle Aspiration Biopsy, and BRAF V600E Mutation. Medicine (Baltimore) (2015) 0.78
Distinguishing molecular markers in thyroid tumors: a tribute to Dr. Orlo Clark. World J Surg (2009) 0.77
Array comparative genomic hybridisation analysis of gamma-irradiated human thyrocytes. Virchows Arch (2004) 0.77
BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrence. Gland Surg (2016) 0.77
Genome-wide expression analysis suggests a crucial role of dysregulation of matrix metalloproteinases pathway in undifferentiated thyroid carcinoma. BMC Genomics (2015) 0.76
Simultaneous occurrence of medullary and papillary thyroid microcarcinomas: a case series and review of the literature. J Med Case Rep (2013) 0.75
BRAFV600E-Associated Gene Expression Profile: Early Changes in the Transcriptome, Based on a Transgenic Mouse Model of Papillary Thyroid Carcinoma. PLoS One (2015) 0.75
Next-generation sequencing in thyroid cancer. J Transl Med (2016) 0.75
Modification, biological evaluation and 3D QSAR studies of novel 2-(1,3-diaryl- 4,5-dihydro-1H-pyrazol-5-yl)phenol derivatives as inhibitors of B-Raf kinase. PLoS One (2014) 0.75
Malignant melanoma and papillary thyroid carcinoma that were diagnosed concurrently and treated simultaneously: A case report. Oncol Lett (2014) 0.75
Associations of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma. PLoS One (2014) 0.75
DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers. PLoS One (2017) 0.75
Association between the BRAF V600E mutation and ultrasound features of the thyroid in thyroid papillary carcinoma. Oncol Lett (2017) 0.75
Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid (2006) 3.03
American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid (2012) 2.71
Demonstration of Epstein-Barr virus in carcinomas of various sites. Cancer Res (2002) 1.88
Thyroidectomy remains an effective treatment option for Graves' disease. Am J Surg (2006) 1.67
Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors. Surgery (2013) 1.62
Splenic fine needle aspiration and core biopsy. A review of 49 cases. Acta Cytol (2003) 1.44
Recurrence after treatment of micropapillary thyroid cancer. Thyroid (2009) 1.41
Synchronous metastases to the liver and pancreas from a primary neuroendocrine carcinoma of the breast diagnosed by fine-needle aspiration. Diagn Cytopathol (2008) 1.35
Are there gender differences in choosing a surgical career? Surgery (2003) 1.28
Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer (2005) 1.26
Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J Clin Endocrinol Metab (2006) 1.24
Intraoperative parathyroid hormone levels in thyroid surgery are predictive of postoperative hypoparathyroidism and need for vitamin D supplementation. Am J Surg (2005) 1.16
Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis. Thyroid (2013) 1.12
Fine-needle aspiration of clinically suspicious palpable breast masses with histopathologic correlation. Am J Surg (2002) 1.11
Heparanase-1 expression is associated with the metastatic potential of breast cancer. Surgery (2002) 1.10
Heparanase-1 gene expression and regulation by high glucose in renal epithelial cells: a potential role in the pathogenesis of proteinuria in diabetic patients. Diabetes (2005) 1.10
Cloning and characterization of the human heparanase-1 (HPR1) gene promoter: role of GA-binding protein and Sp1 in regulating HPR1 basal promoter activity. J Biol Chem (2002) 1.09
Expression of hypothalamic-pituitary-thyroid axis related genes in the human skin. J Invest Dermatol (2002) 1.09
Human papillomavirus and p16 expression in inverted papillomas of the urinary bladder. Cancer Lett (2009) 1.08
Thyroglobulin: a specific serum marker for the management of thyroid carcinoma. Clin Lab Med (2004) 1.07
Update on human polyomavirus BK nephropathy. Diagn Cytopathol (2009) 1.05
Incidental papillary carcinoma in patients treated surgically for benign thyroid diseases. Surgery (2009) 1.05
Participants' opinions of laparoscopic training devices after a basic laparoscopic training course. Am J Surg (2005) 1.04
Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression. BMC Cancer (2011) 1.04
Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid (2010) 1.04
Management of biliary and duodenal complications of chronic pancreatitis. World J Surg (2003) 1.03
A CRASH course in procedural skills improves medical students' self-assessment of proficiency, confidence, and anxiety. Am J Surg (2007) 1.03
Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Breast J (2005) 1.03
Esophageal stenting in the setting of malignancy. ISRN Gastroenterol (2011) 1.01
Medical students' perceptions of resident teaching: have duty hours regulations had an impact? Ann Surg (2005) 0.99
Somatostatin analog treatment of a cervical thoracic duct fistula. Head Neck (2002) 0.98
Elevated serum heparanase-1 levels in patients with pancreatic carcinoma are associated with poor survival. Cancer (2006) 0.97
The challenging estrogen receptor-negative/ progesterone receptor-negative/HER-2-negative patient: a promising candidate for epidermal growth factor receptor-targeted therapy? Breast J (2006) 0.96
Inverse correlation between heparan sulfate composition and heparanase-1 gene expression in thyroid papillary carcinomas: a potential role in tumor metastasis. Clin Cancer Res (2003) 0.96
Cytologic features of meningiomas on crush preparations: a review. Diagn Cytopathol (2008) 0.96
Human heparanase-1 gene expression in pancreatic adenocarcinoma. J Gastrointest Surg (2002) 0.95
Central pancreatectomy for the resection of benign or low malignant potential neoplasms. World J Surg (2003) 0.94
Outcome of laparoscopic adrenalectomy for pheochromocytomas vs aldosteronomas. Arch Surg (2004) 0.94
Parathyroidectomy outcomes according to operative approach. Am J Surg (2007) 0.93
Brush cytology of the biliary tract: retrospective study of 278 cases with histopathologic correlation. Diagn Cytopathol (2002) 0.93
Intraoperative PTH monitoring in parathyroid hyperplasia requires stricter criteria for success. Surgery (2004) 0.92
Adult granulosa cell tumor of the ovary: fine-needle-aspiration cytology of 10 cases and review of literature. Diagn Cytopathol (2008) 0.92
Benefits of surgeon-performed ultrasound for primary hyperparathyroidism. Langenbecks Arch Surg (2009) 0.91
Activation of the Sonic Hedgehog pathway in thyroid neoplasms and its potential role in tumor cell proliferation. Endocr Relat Cancer (2012) 0.90
Nup88 (karyoporin) in human malignant neoplasms and dysplasias: correlations of immunostaining of tissue sections, cytologic smears, and immunoblot analysis. Hum Pathol (2002) 0.90
Primary hyperaldosteronism in the era of laparoscopic adrenalectomy. Am Surg (2002) 0.89
An algorithm to maximize use of minimally invasive parathyroidectomy. Arch Surg (2004) 0.89
Reversible cognitive, motor, and driving impairments in severe hypothyroidism. Thyroid (2015) 0.89
In vivo and in vitro degradation of heparan sulfate (HS) proteoglycans by HPR1 in pancreatic adenocarcinomas. Loss of cell surface HS suppresses fibroblast growth factor 2-mediated cell signaling and proliferation. J Biol Chem (2006) 0.89
Well-differentiated neuroendocrine carcinomas: the spectrum of histologic subtypes and various clinical behaviors. Semin Thorac Cardiovasc Surg (2006) 0.89
Prognostic value of xanthine oxidoreductase expression in patients with non-small cell lung cancer. Lung Cancer (2010) 0.89
Anorectal anatomy and embryology. Surg Oncol Clin N Am (2004) 0.88
The sonic hedgehog signaling pathway maintains the cancer stem cell self-renewal of anaplastic thyroid cancer by inducing snail expression. J Clin Endocrinol Metab (2014) 0.88
Unusual cases of metastases to the breast. A report of 17 cases diagnosed by fine needle aspiration. Acta Cytol (2002) 0.88
Greater local recurrence occurs with "berry picking" than neck dissection in thyroid cancer. Am Surg (2003) 0.87
Lupus mastitis: an uncommon complication of systemic or discoid lupus. Am J Surg Pathol (2010) 0.87
Right middle lobectomy for a primary pulmonary leiomyoma: a case report. Cases J (2009) 0.87
Ductal carcinoma in situ of the breast and heparanase-1 expression: a molecular explanation for more aggressive subtypes. J Am Coll Surg (2005) 0.86
A 40-year-old male with an intraventricular tumor. Combined tanycytic ependymoma and subependymoma. Brain Pathol (2013) 0.86
Estradiol induces heparanase-1 expression and heparan sulphate proteoglycan degradation in human endometrium. Hum Reprod (2007) 0.86
Fine-needle aspiration diagnosis of a metastatic adult sclerosing rhabdomyosarcoma in a lymph node. Diagn Cytopathol (2010) 0.86
Cytologic features of granular cell astrocytoma in crush preparations. Diagn Cytopathol (2011) 0.85
Surgical management of well-differentiated thyroid cancer locally invasive to the respiratory tract. J Am Coll Surg (2005) 0.84
Intraoperative total serum calcium levels, unlike intraoperative intact PTH levels, do not correlate with cure of hyperparathyroidism. J Surg Res (2003) 0.84
Clinicopathological significance of major histocompatibility complex class I-related chain a and B expression in thyroid cancer. J Clin Endocrinol Metab (2006) 0.84
Pheochromocytoma presenting with multiple organ failure. Am Surg (2008) 0.84
Renal leiomyoma: a contemporary multi-institution study of an infrequent and frequently misclassified neoplasm. Am J Surg Pathol (2015) 0.83
Reed-Sternberg cells in bronchial brushings from a patient with Hodgkin's disease. Diagn Cytopathol (2006) 0.83
A prospective evaluation of the effect of sample collection site on intraoperative parathormone monitoring during parathyroidectomy. Surgery (2008) 0.83
Short-term outcomes of parathyroidectomy in patients with or without 25-hydroxy vitamin D insufficiency. J Surg Res (2007) 0.82
Induction of heparanase-1 expression by mutant B-Raf kinase: role of GA binding protein in heparanase-1 promoter activation. Neoplasia (2010) 0.82
Morphologic features of endometriosis in various types of cytologic specimens. Diagn Cytopathol (2013) 0.82
Oral vitamin D supplementation reduces the incidence of eucalcemic PTH elevation after surgery for primary hyperparathyroidism. Surgery (2007) 0.82
Bilateral synchronous pleomorphic adenoma diagnosed by fine-needle aspiration. Diagn Cytopathol (2004) 0.82
Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors. Thyroid (2002) 0.81
Fine-needle aspiration of primary Rosai-Dorfman disease of the bone without peripheral lymphadenopathy: a challenging diagnosis. Diagn Cytopathol (2011) 0.81
Correlation of clinicopathologic parameters and immunohistochemical features of triple-negative invasive lobular carcinoma. Appl Immunohistochem Mol Morphol (2014) 0.81
An unusual case of Aspergillus fibrosing mediastinitis. Ann Thorac Surg (2009) 0.81
Diagnosis of blastomycosis in surgical pathology and cytopathology: correlation with microbiologic culture. Am J Surg Pathol (2010) 0.81
Outcomes of pheochromocytoma management in the laparoscopic era. Ann Surg Oncol (2007) 0.81
Fine-needle aspiration of metanephric adenoma of the kidney with clinical, radiographic and histopathologic correlation: a review. Diagn Cytopathol (2013) 0.81